Investing.com - Amylyx Pharmaceuticals (NASDAQ: AMLX) reported second quarter EPS of $0.31, $0.12 better than the analyst estimate of $0.19. Revenue for the quarter came in at $98.22M versus the consensus estimate of $92.14M.
Amylyx Pharmaceuticals's stock price closed at $21.17. It is down -23.49% in the last 3 months and down -18.58% in the last 12 months.
Amylyx Pharmaceuticals saw 2 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Amylyx Pharmaceuticals's stock price’s past reactions to earnings here.
According to InvestingPro, Amylyx Pharmaceuticals's Financial Health score is "good performance".
Check out Amylyx Pharmaceuticals's recent earnings performance, and Amylyx Pharmaceuticals's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar